Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy
This study has been completed.
Study NCT00000842 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: November 2, 1999 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Peripheral Nervous System Disease
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Infection
Nervous System Diseases
Peripheral Nervous System Diseases
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Neuromuscular Diseases
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Additional drug interventions recognized in this trial
Mitogens
More general drug interventions related to this trial
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Back to top of Main Content
